Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This case study reports significant improvements in joint pain and hair regrowth in a 31-year-old female with alopecia universalis, psoriasis vulgaris, and psoriatic arthritis using a combination of tofacitinib and methotrexate after other treatments failed.

In this study, nearly 5% of anti-TNF-treated patients with IBD developed psoriasiform skin lesions, with smoking identified as a main risk factor, and ustekinumab proved highly effective in severe cases.

This review highlights the impact of obesity on skin health, detailing how it alters skin barrier function, exacerbates conditions like Psoriasis, and is linked to various skin complications without reporting new clinical results.

This review discusses the complex skin changes associated with obesity and the potential benefits of nutritional interventions for inflammatory skin diseases, without reporting new clinical results.

This review discusses the skin manifestations associated with metabolic syndrome and related conditions in young populations, noting associations with obesity, insulin resistance, and neonatal obesity, but reports no new clinical results.

This study found that topical oxygen therapy may be a beneficial adjuvant treatment for hair loss, acne, and chronic dermatological conditions, though further research is needed to confirm its effectiveness.

This narrative review reports that IL-17 and IL-23 inhibitors, while effective for psoriasis and other inflammatory diseases, can cause a variety of skin reactions that resemble primary dermatoses, highlighting the need for careful diagnosis and varied management strategies.

This review reported on botulinum toxin's potential in treating dermatological conditions like hidradenitis suppurativa, rosacea, androgenetic alopecia, plaque psoriasis, and primary hyperhidrosis, highlighting initial efficacy but indicating a need for controlled trials to confirm safety and effectiveness.

This study found that the oral Janus kinase inhibitor CP-690,550 has a direct effect on reducing pruritus in patients with psoriasis, independent of clinician-assessed improvements in psoriasis severity.

In this study, dose-response modeling predicted that once-daily abrocitinib doses of 100 mg and 200 mg may provide a clinically meaningful response in treating moderate-to-severe atopic dermatitis compared to placebo.

This article discusses recent advancements in treatments for psoriasis, including new drug approvals and innovative therapeutic approaches, but reports no new clinical results.

This review discusses various dermatological scoring systems used to objectively assess disease severity and guide treatment decisions, reporting no new clinical results.

This Mendelian randomization study suggests a causal link between higher BMI and increased risk of psoriasis, atopic dermatitis, and hidradenitis suppurativa, potentially due to elevated biomarkers such as triglycerides and C-reactive protein.

Real-life dosing of biologics for plaque psoriasis often deviates from recommended guidelines, especially for high-need patients.

This vodcast discusses various tools for assessing the severity of alopecia areata, emphasizing the importance of considering psychosocial impacts alongside physical symptoms.

This study found that the Cutaneous Lupus Disease Area and Severity Index (CLASI) is correlated with both physician-assessed and patient-reported outcomes in cutaneous lupus erythematosus, particularly highlighting concerns about body image in visible areas.

This study found that short-term NB-UVB treatment significantly reduced anxiety levels in psoriasis patients, but not depression.

This study found that using calcipotriene and betamethasone dipropionate cream in a real-world setting significantly improved clinical outcomes and patient quality of life for adults with mild-to-moderate scalp psoriasis, especially among those with higher adherence, demonstrating high treatment satisfaction.

This clinical study found that using a cream or lotion as an additional treatment alongside standard care for atopic dermatitis significantly reduced symptoms and improved skin moisturization and barrier function within 28 days compared to standard care alone in participants with mild-to-moderate eczema.

This study found that alopecia areata negatively affects patients' quality of life, though less severely than psoriasis, atopic dermatitis, and onychomycosis.

Tildrakizumab significantly improved psoriasis symptoms and well-being over 52 weeks.

This study reported that AutoML effectively modeled itching and pain development, as well as app use, in patients with chronic eczema or psoriasis using a smartphone monitoring app, revealing that factors like BMI, age, and disease activity significantly influenced app engagement.

This chapter reviews the development of skin-specific outcome instruments for autoimmune diseases like cutaneous lupus erythematosus and dermatomyositis, highlighting a need for a broader community-involved process across other diseases but reports no new results.

The document focused on hair disorders, especially alopecia, and discussed treatments and impacts on quality of life.

This study found that videodermoscopy can help diagnose nailbed psoriasis by revealing distinctive hyponychial capillary patterns, which correlated with disease severity and response to treatment.

This article discusses the potential of oral tofacitinib as a treatment for atopic dermatitis, alopecia areata, and vitiligo, without presenting new clinical results.

This study suggests that for dermatomyositis patients with minimal skin disease activity, further improvement in cutaneous symptoms may not translate into better quality of life, highlighting a need to revise trial endpoints.

This review discusses the potential causes and treatments for frontal fibrosing alopecia but reports no new clinical findings, highlighting the need for further research to understand its pathogenesis and develop validated treatments.

Psoriasis patients experience moderate functional impairment related to disease severity and less satisfaction.

This study found that patients with alopecia areata had higher systemic inflammation markers compared to healthy controls, and these markers were associated with a greater risk of severe disease.